Drug
GSK2315698
GSK2315698 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
NCT01777243
completedphase_1
SAP Depleter Dose Escalation Study in Healthy Volunteers
NCT01323985
completedphase_1
SAP Depleter Dose Assessment Study in Patients
NCT01406314
completedphase_1
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
NCT02953808
Clinical Trials (4)
Showing 4 of 4 trials
NCT01777243Phase 1
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
NCT01323985Phase 1
SAP Depleter Dose Escalation Study in Healthy Volunteers
NCT01406314Phase 1
SAP Depleter Dose Assessment Study in Patients
NCT02953808Phase 1
Phase 1 Study of GSK2315698 in Healthy Japanese Subjects
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4